Pharma And The CIA
This article was originally published in Scrip
Three years ago, nine of top 10 and 12 of the top 20 pharma companies were bound by five-year pledges signed with the US Department of Health & Human Services' Office of Inspector General following cases investigating misconduct. Not an ideal state of affairs for an industry desperate to improve its reputation.
You may also be interested in...
Novo exec says CIAs can help spur culture change to improve sales rep compliance; cooperation can also help avoid corporate integrity agreements in future settlements.
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.